The U.S. FDA has approved Leqembi for Alzheimer’s treatment, which slows cognitive decline, but the Centers for Medicare & Medicaid Services have not committed to covering the necessary PET scans, according to Society of Nuclear Medicine and Molecular Imaging officials.
Researchers have developed an approach to estimating when a person who is likely to develop Alzheimer’s disease, but has no cognitive symptoms, will start showing signs of Alzheimer’s dementia.
Immuno-PET imaging can provide early insight into a tumor’s response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.
Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds.
Read More
Researchers have validated a new radiolabeled molecule that can be used with imaging tests to accurately detect and characterize brain injury.
Read MoreFindings based on analysis of MRI and PET scans suggest recurring falls could point to the development of Alzheimer’s Disease in older adults.
Read More
Findings from a new study showing the connection between impaired blood flow and the build-up of tau protein in MRI and PET scans suggest Alzheimer’s patients may benefit from a combination treatment.
Read More
Results from the first study using uEXPLORER to conduct total-body dynamic PET scans in cancer patients show that it can be used to generate high-quality images of metastatic cancer.
Read More